211 related articles for article (PubMed ID: 34601294)
21. Design, synthesis, modelling studies and biological evaluation of 1,3,4-oxadiazole derivatives as potent anticancer agents targeting thymidine phosphorylase enzyme.
Bajaj S; Kumar MS; Tinwala H; Yc M
Bioorg Chem; 2021 Jun; 111():104873. PubMed ID: 33845381
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.
Zhang XM; Qiu M; Sun J; Zhang YB; Yang YS; Wang XL; Tang JF; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(21):6518-24. PubMed ID: 21962523
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Yuan X; Bu H; Zhou J; Yang CY; Zhang H
J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
Zeng LF; Zhang RY; Yu ZH; Li S; Wu L; Gunawan AM; Lane BS; Mali RS; Li X; Chan RJ; Kapur R; Wells CD; Zhang ZY
J Med Chem; 2014 Aug; 57(15):6594-609. PubMed ID: 25003231
[TBL] [Abstract][Full Text] [Related]
25. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
[TBL] [Abstract][Full Text] [Related]
26. Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
Wu X; Xu G; Li X; Xu W; Li Q; Liu W; Kirby KA; Loh ML; Li J; Sarafianos SG; Qu CK
J Med Chem; 2019 Feb; 62(3):1125-1137. PubMed ID: 30457860
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent.
Sun J; Zhu H; Yang ZM; Zhu HL
Eur J Med Chem; 2013 Feb; 60():23-8. PubMed ID: 23279864
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and
Alzhrani ZMM; Alam MM; Neamatallah T; Nazreen S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1116-1123. PubMed ID: 32354237
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
30. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
Lade DM; Nicoletti R; Mersch J; Agazie YM
Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
[TBL] [Abstract][Full Text] [Related]
32. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
[TBL] [Abstract][Full Text] [Related]
33. Novel PROTACs for degradation of SHP2 protein.
Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
Zhen XL; Yin WH; Tian X; Ma ZJ; Fan SM; Han JR; Liu S
Bioorg Med Chem; 2015 May; 23(10):2562-7. PubMed ID: 25865131
[TBL] [Abstract][Full Text] [Related]
35. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.
Lawrence HR; Pireddu R; Chen L; Luo Y; Sung SS; Szymanski AM; Yip ML; Guida WC; Sebti SM; Wu J; Lawrence NJ
J Med Chem; 2008 Aug; 51(16):4948-56. PubMed ID: 18680359
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wu J; Li W; Zheng Z; Lu X; Zhang H; Ma Y; Wang R
J Biomol Struct Dyn; 2021 Mar; 39(4):1174-1188. PubMed ID: 32036779
[TBL] [Abstract][Full Text] [Related]
38. Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Lee YJ; Song H; Yoon YJ; Park SJ; Kim SY; Cho Han D; Kwon BM
Biochem Pharmacol; 2020 May; 175():113920. PubMed ID: 32201212
[TBL] [Abstract][Full Text] [Related]
39. Design potential selective inhibitors for treating cancer by targeting the Src homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping approach.
Duan YQ; Ma Y; Wang XJ; Jin YY; Wang RL; Dong WL; Xu WR; Kong DX; Wang SQ
Protein Pept Lett; 2014 Jun; 21(6):556-63. PubMed ID: 24364859
[TBL] [Abstract][Full Text] [Related]
40. 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.
Sarver P; Acker M; Bagdanoff JT; Chen Z; Chen YN; Chan H; Firestone B; Fodor M; Fortanet J; Hao H; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu G; Liu S; Liu C; McNeill E; Mohseni M; Sendzik M; Stams T; Spence S; Tamez V; Tichkule R; Towler C; Wang H; Wang P; Williams SL; Yu B; LaMarche MJ
J Med Chem; 2019 Feb; 62(4):1793-1802. PubMed ID: 30688459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]